In neurological research, similar approaches have been employed to either suppress the activity of disease-associated genes by introducing methyl groups or to demethylate nonfunctional genes, specifically MECP2 and FMR1, in cellular models of Rett syndrome and FXS, respectively [53]. Here, MECP2 is linked to fragile X syndrome.